Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from diff erent tissue sites

Adam K. Ahrens, Nagendra K. Chaturvedi, Tara M. Nordgren, Bhavana J Dave, Shantaram S Joshi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) is a rare but aggressive form of B cell non-Hodgkin lymphoma in which therapy resistance is common. New therapeutic options have extended survival in refractory MCL but have not provided durable remission. Tools are needed to assess the molecular and genetic changes associated with therapy resistance. Therefore, therapy-resistant MCL cell lines were established from the liver, kidney and lungs of human Granta 519-bearing NOD-SCID (non-obese diabetic-severe combined immunodeficiency) mice following treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy in combination with bortezomib. The cytomorphologies, immunophenotypes, growth patterns in semi-solid agar, cytogenetic profiles and gene expression differences between these cell lines were characterized to identify major changes associated with therapy resistance. Therapy-resistant cell lines exhibit more aggressive growth patterns and markedly different gene expression profiles compared to parental Granta 519 cells. Thus, these stable therapy-resistant cell lines are useful models to further study the molecular basis of drug resistance and to identify clinically relevant molecular targets in MCL.

Original languageEnglish (US)
Pages (from-to)2269-2278
Number of pages10
JournalLeukemia and Lymphoma
Volume53
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Mantle-Cell Lymphoma
Cell Line
Therapeutics
Transcriptome
Severe Combined Immunodeficiency
Vincristine
B-Cell Lymphoma
Growth
Prednisone
Combination Drug Therapy
Drug Resistance
Cytogenetics
Non-Hodgkin's Lymphoma
Doxorubicin
Cyclophosphamide
Agar
Molecular Biology
Kidney
Lung
Survival

Keywords

  • Mantle cell lymphoma
  • gene expression analyses
  • therapy-resistant cell lines

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from diff erent tissue sites. / Ahrens, Adam K.; Chaturvedi, Nagendra K.; Nordgren, Tara M.; Dave, Bhavana J; Joshi, Shantaram S.

In: Leukemia and Lymphoma, Vol. 53, No. 11, 01.11.2012, p. 2269-2278.

Research output: Contribution to journalArticle

@article{4888150e22fe445b85de14e42486df9f,
title = "Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from diff erent tissue sites",
abstract = "Mantle cell lymphoma (MCL) is a rare but aggressive form of B cell non-Hodgkin lymphoma in which therapy resistance is common. New therapeutic options have extended survival in refractory MCL but have not provided durable remission. Tools are needed to assess the molecular and genetic changes associated with therapy resistance. Therefore, therapy-resistant MCL cell lines were established from the liver, kidney and lungs of human Granta 519-bearing NOD-SCID (non-obese diabetic-severe combined immunodeficiency) mice following treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy in combination with bortezomib. The cytomorphologies, immunophenotypes, growth patterns in semi-solid agar, cytogenetic profiles and gene expression differences between these cell lines were characterized to identify major changes associated with therapy resistance. Therapy-resistant cell lines exhibit more aggressive growth patterns and markedly different gene expression profiles compared to parental Granta 519 cells. Thus, these stable therapy-resistant cell lines are useful models to further study the molecular basis of drug resistance and to identify clinically relevant molecular targets in MCL.",
keywords = "Mantle cell lymphoma, gene expression analyses, therapy-resistant cell lines",
author = "Ahrens, {Adam K.} and Chaturvedi, {Nagendra K.} and Nordgren, {Tara M.} and Dave, {Bhavana J} and Joshi, {Shantaram S}",
year = "2012",
month = "11",
day = "1",
doi = "10.3109/10428194.2012.691481",
language = "English (US)",
volume = "53",
pages = "2269--2278",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from diff erent tissue sites

AU - Ahrens, Adam K.

AU - Chaturvedi, Nagendra K.

AU - Nordgren, Tara M.

AU - Dave, Bhavana J

AU - Joshi, Shantaram S

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Mantle cell lymphoma (MCL) is a rare but aggressive form of B cell non-Hodgkin lymphoma in which therapy resistance is common. New therapeutic options have extended survival in refractory MCL but have not provided durable remission. Tools are needed to assess the molecular and genetic changes associated with therapy resistance. Therefore, therapy-resistant MCL cell lines were established from the liver, kidney and lungs of human Granta 519-bearing NOD-SCID (non-obese diabetic-severe combined immunodeficiency) mice following treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy in combination with bortezomib. The cytomorphologies, immunophenotypes, growth patterns in semi-solid agar, cytogenetic profiles and gene expression differences between these cell lines were characterized to identify major changes associated with therapy resistance. Therapy-resistant cell lines exhibit more aggressive growth patterns and markedly different gene expression profiles compared to parental Granta 519 cells. Thus, these stable therapy-resistant cell lines are useful models to further study the molecular basis of drug resistance and to identify clinically relevant molecular targets in MCL.

AB - Mantle cell lymphoma (MCL) is a rare but aggressive form of B cell non-Hodgkin lymphoma in which therapy resistance is common. New therapeutic options have extended survival in refractory MCL but have not provided durable remission. Tools are needed to assess the molecular and genetic changes associated with therapy resistance. Therefore, therapy-resistant MCL cell lines were established from the liver, kidney and lungs of human Granta 519-bearing NOD-SCID (non-obese diabetic-severe combined immunodeficiency) mice following treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy in combination with bortezomib. The cytomorphologies, immunophenotypes, growth patterns in semi-solid agar, cytogenetic profiles and gene expression differences between these cell lines were characterized to identify major changes associated with therapy resistance. Therapy-resistant cell lines exhibit more aggressive growth patterns and markedly different gene expression profiles compared to parental Granta 519 cells. Thus, these stable therapy-resistant cell lines are useful models to further study the molecular basis of drug resistance and to identify clinically relevant molecular targets in MCL.

KW - Mantle cell lymphoma

KW - gene expression analyses

KW - therapy-resistant cell lines

UR - http://www.scopus.com/inward/record.url?scp=84867164906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867164906&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.691481

DO - 10.3109/10428194.2012.691481

M3 - Article

VL - 53

SP - 2269

EP - 2278

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -